Clinical and methodologic considerations with regard to a trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: comment on the reanalysis by Maher et al

被引：1
|
作者：
Bredemeier, Markus [1 ]
机构：
[1] Hosp Nossa Senhora Conceicao, Conceicao Hosp Grp, Porto Alegre, RS, Brazil
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年
关键词：
D O I：
10.1002/art.41893
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2518 - 2528
  • [2] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Andreasson, Kristofer
    Wuttge, Dirk M.
    Wollheim, Frank A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1595 - 1596
  • [3] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (11): : E755 - E755
  • [4] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Rahimi, Susan
    LANCET RESPIRATORY MEDICINE, 2020, 8 (02): : 136 - 136
  • [5] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease REPLY
    Distler, Oliver
    Gahlemann, Martina
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1596 - 1597
  • [6] Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
    Yamasaki, Yoshioki
    Kuwana, Masataka
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (06) : 547 - 560
  • [7] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial
    Kuwana, Masataka
    Ogura, Takashi
    Makino, Shigeki
    Homma, Sakae
    Kondoh, Yasuhiro
    Saito, Aiko
    Ugai, Hiroyuki
    Gahlemann, Martina
    Takehara, Kazuhiko
    Azuma, Arata
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 141 - 150
  • [8] Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): The SENSCIS Trial
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Fischer, A.
    Mayes, M.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial
    Prasse, A.
    Distler, O.
    Highland, K. B.
    Gahlemann, M.
    Azuma, A.
    Mayes, M. D.
    Raghu, G.
    Sauter, W.
    Girard, M.
    Alves, M.
    Clerisme-Beaty, E.
    Kuwana, M.
    Maher, T. M.
    PNEUMOLOGIE, 2020, 74 : S57 - S58
  • [10] Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)
    Distler, O.
    Brown, K. K.
    Distler, J. H. W.
    Assassi, S.
    Maher, T. M.
    Cottin, V.
    Varga, J.
    Coeck, C.
    Gahlemann, M.
    Sauter, W.
    Schmidt, H.
    Highland, K. B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : S75 - S81
12345